Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CCCC 
C4 Therapeutics Inc (CCCC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: CCCC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $15
1 Year Target Price $15
| 4 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -29.84% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 176.50M USD | Price to earnings Ratio - | 1Y Target Price 15 |
Price to earnings Ratio - | 1Y Target Price 15 | ||
Volume (30-day avg) 8 | Beta 2.96 | 52 Weeks Range 1.08 - 6.52 | Updated Date 10/17/2025 |
52 Weeks Range 1.08 - 6.52 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.59 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -440.99% |
Management Effectiveness
Return on Assets (TTM) -22.8% | Return on Equity (TTM) -52.99% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5656501 | Price to Sales(TTM) 5.15 |
Enterprise Value 5656501 | Price to Sales(TTM) 5.15 | ||
Enterprise Value to Revenue 0.17 | Enterprise Value to EBITDA -0.42 | Shares Outstanding 71170815 | Shares Floating 50158344 |
Shares Outstanding 71170815 | Shares Floating 50158344 | ||
Percent Insiders 9.78 | Percent Institutions 76.85 |
Upturn AI SWOT
C4 Therapeutics Inc
Company Overview
History and Background
C4 Therapeutics, Inc. (CCCC) was founded in 2011 and is a biopharmaceutical company focusing on developing targeted protein degradation therapies to treat cancer, inflammation, and neurodegenerative diseases. The company has evolved from its early research focus to a clinical-stage organization with multiple ongoing clinical trials.
Core Business Areas
- Targeted Protein Degradation: C4 Therapeutics focuses on discovering and developing small-molecule drugs that selectively degrade disease-causing proteins. Their approach utilizes the ubiquitin-proteasome system (UPS), the cell's natural mechanism for protein degradation.
- Oncology: The primary focus is on developing treatments for various cancers with high unmet medical needs.
Leadership and Structure
Andrew Hirsch is the President and Chief Executive Officer. The company has a board of directors and a management team overseeing research, development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- CFT7455: A MonoC degradation program targeting MYC. It is in Phase 1/2 clinical trials for advanced malignancies. Market share data is not yet applicable due to its developmental stage. Competitors include companies developing MYC inhibitors.
- CFT1946: A BiDAC degrader targeting BRAF V600E. It is in Phase 1/2 clinical trials for BRAF V600E-mutant solid tumors. Market share data is not yet applicable due to its developmental stage. Competitors include companies developing BRAF inhibitors.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, marked by innovation, regulatory hurdles, and significant investment in R&D. Protein degradation is an emerging field with significant potential.
Positioning
C4 Therapeutics is positioned as a leader in the targeted protein degradation field, leveraging its TORPEDO platform. The company's competitive advantage lies in its proprietary technology and expertise in protein degradation.
Total Addressable Market (TAM)
The total addressable market for targeted protein degradation therapies is estimated to be in the tens of billions of dollars, driven by the unmet needs in oncology and other therapeutic areas. C4 Therapeutics aims to capture a significant share of this market with its pipeline of novel therapies.
Upturn SWOT Analysis
Strengths
- Proprietary TORPEDO platform
- Strong intellectual property position
- Experienced management team
- Pipeline of novel protein degraders
Weaknesses
- Limited revenue stream
- High R&D expenses
- Dependence on clinical trial success
- Competition in the protein degradation field
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into new therapeutic areas
- Advancement of clinical programs
- Increasing adoption of protein degradation therapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other protein degradation companies
- Patent challenges
Competitors and Market Share
Key Competitors
- KYMR
- ARVN
Competitive Landscape
C4 Therapeutics faces competition from other companies developing targeted protein degradation therapies, as well as established pharmaceutical companies developing treatments for the same diseases. C4 Therapeutics differentiates itself through its proprietary technology platform and focus on novel targets.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth is reflected in advancing their clinical programs and establishing partnerships.
Future Projections: Future growth is dependent on clinical trial successes and potential commercialization of their therapies. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing clinical trials for CFT7455 and CFT1946, presenting clinical data at medical conferences, and exploring new therapeutic targets.
Summary
C4 Therapeutics is a clinical-stage biopharmaceutical company pioneering targeted protein degradation therapies, particularly in oncology. The company holds significant potential with its innovative TORPEDO platform and pipeline of novel degraders. Success hinges on positive clinical trial outcomes and effective market positioning in a competitive landscape. Key risks include clinical trial failures, regulatory challenges, and competition. Continued advancements in clinical trials and strategic partnerships are crucial for sustainable growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About C4 Therapeutics Inc
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2020-10-02 | CEO, President & Director Mr. Andrew J. Hirsch M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 110 | Website https://www.c4therapeutics.com |
Full time employees 110 | Website https://www.c4therapeutics.com | ||
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.